Cns Pharmaceuticals Inc
(NQ:
CNSP
)
0.1432
-0.0068 (-4.53%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cns Pharmaceuticals Inc
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at Virtual Investor 2023 ‘Companies to Watch’
January 05, 2023
Via
Investor Brand Network
Four Developments in Cancer Research That Occurred in 2022
January 05, 2023
Via
Investor Brand Network
Topics
Death
Exposures
Death
Product Safety
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Strategic Board Appointment of Faith L. Charles, JD
January 03, 2023
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Continues to See Growth in Patient Enrollment for Brain Cancer Drug Candidate Global Clinical Trial
December 28, 2022
Via
Investor Brand Network
Four Facts You Need to Know About Brain Cancer
November 29, 2022
Via
Investor Brand Network
Machine Learning Effort Enables Large-Scale Cancer Study to Improve Boundary Detection
December 27, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations
December 22, 2022
Via
Investor Brand Network
New Study Finds Localized Cooling of Brain Tumors Slows Growth in Mice Models
December 19, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Berubicin Program Forward
December 14, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment
December 14, 2022
Via
Investor Brand Network
Data Shows Increase in Mortality Among Patients with Malignant Brain Tumors
December 12, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin
December 12, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Preliminary Results from Berubicin Trial
December 08, 2022
Via
Investor Brand Network
Research Recommends Reduction of Pediatric Brain Irradiation During Cancer Treatment
December 05, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in ‘Ask the CEO’ Event
December 05, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Pricing for Public Offering
December 01, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place
November 29, 2022
Via
Investor Brand Network
European Clinical Trial Site Expansion for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Brain Cancer Drug Candidate Drives Patient Enrollment
November 28, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Seeking to Solve Unmet Need for GBM Treatment
November 23, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Announces First European Dosing in Potentially Pivotal GBM Trial
November 22, 2022
Via
Investor Brand Network
Implanted Pump Holds Promise in Treating Brain Cancer
November 21, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations
November 16, 2022
Via
Investor Brand Network
Researchers Turn to AI for Insights on Treating Brain Tumors
November 15, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2022 Financial Numbers, Corporate Update
November 15, 2022
Via
Investor Brand Network
Scientists Look for Ways to Disable Sugar Molecule That Fuels Cancer Persistence
November 14, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin
November 14, 2022
Via
Investor Brand Network
Research Finds New Therapy Path for Brain Cancer
November 10, 2022
Via
Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM
November 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Targeted ‘Finish Line Is Within Sight’ as It Pursues Potential GBM Treatment
November 07, 2022
Via
Investor Brand Network
New Brain Cancer Clinical Trial Platform Launched in Australia
November 07, 2022
Via
Investor Brand Network
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.